ACC announces late-breaking science lineup for 2023 Scientific Session

Fact checked byErik Swain

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 4-6, 2023 in New Orleans and online.

The lineup is as follows:

microphone at meeting — The ACC announced the late-breaking science lineup for its Scientific Session to be held March 4-6, 2023 in New Orleans and online.
*Source: Adobe Stock*

Late-Breaking Clinical Trials I: Joint ACC/Journal of the American College of Cardiology Late-Breaking Clinical Trials

the CLEAR outcomes trial of bempedoic acid (Nexletol, Esperion Therapeutics) in statin-intolerant patients at high CV risk;
the TRILUMINATE pivotal trial of transcatheter tricuspid valve edge-to-edge repair (TriClip, Abbott) for tricuspid regurgitation; and
the STOP-CA trial of statins for the prevention of cardiotoxicity from anthracyclines.

Late-Breaking Clinical Trials II: Joint ACC/New England Journal of Medicine Late-Breaking Clinical Trials

the UK Mini trial of minimally invasive compared with conventional sternotomy for mitral valve repair surgery;
the final 5-year results from the COAPT trial of transcatheter edge-to-edge repair (MitraClip, Abbott) for functional mitral regurgitation in HF;
the 3-year outcomes of the Evolut Low Risk Trial of transcatheter (CoreValve, Evolut R or Evolut PRO; Medtronic) compared with surgical aortic valve replacement in patients with aortic stenosis at low surgical risk;
the BIOVASC trial of complete revascularization strategies for patients with ACS and multivessel coronary disease; and
the RENOVATE-COMPLEX-PCI of IV imaging-guided compared with angiography-guided optimization of complex PCI.

Late-Breaking Clinical Trials III

the BETTER CARE-HF trial of electronic tools to enhance and reinforce CV recommendations for HF;
the NUDGE-FLU nationwide randomized trial of electronically delivered nudges to increase influenza vaccination;
the PCDS statin trial of a personalized clinical decision support intervention to improve statin prescribing in patients with atherosclerotic CVD;
a trial translating polygenic risk for CAD into clinically actionable information using causal artificial intelligence; and
the ACCESS trial that assessed the impact of eliminating copayment for high-value preventive medications for low-income seniors with chronic CVDs.

Late-Breaking Clinical Trials IV: Joint ACC/Journal of the American Medical Association Late-Breaking Clinical Trials

the Pulsed AF pivotal trial of pulsed field ablation treatment (PulseSelect PFA System, Medtronic) for paroxysmal and persistent AF;
the BMAD trial of HF management using thoracic fluid monitoring from a novel wearable sensor (Microcor, Zoll);
a trial assessing a novel wrist-worn transdermal troponin-I sensor for acute MI;
the phase III A DUE study of the efficacy and safety of fixed dose combination macitentan and tadalafil (Actelion) in pulmonary arterial hypertension; and
the COORDINATE Diabetes trial of interventions to improve outcomes in diabetes.

Late-Breaking Clinical Trials V

the LIVE-HCM study of vigorous exercise in patients with hypertrophic cardiomyopathy;
a trial assessing return-to-play for elite level athletes with sudden cardiac death-predisposing genetic heart diseases;
the Freedom Covid Anticoagulation trial assessing anticoagulation strategies in non-critically ill, hospitalized patients with COVID-19;
the STELLAR phase III trial of combination sotatercept (Acceleron/Merck) with background therapy for pulmonary arterial hypertension; and
a phase 2b trial assessing the efficacy and safety of the oral PCSK9 inhibitor MK-0616 (Merck) for the treatment of hypercholesterolemia.

Healio | Cardiology Today will be onsite in New Orleans to report the latest news from the ACC Scientific Session, with physician perspective, researcher interviews and more. Follow our breaking updates here and via @CardiologyToday on Twitter.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

American College of Cardiology

Read more